Press coverage about Cara Therapeutics (NASDAQ:CARA) has trended somewhat positive on Thursday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cara Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 48.0614564965077 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Should You Be Concerned About Cara Therapeutics Inc’s (NASDAQ:CARA) Earnings Growth? (finance.yahoo.com)
- Cara Therapeutics (CARA) Price Target Cut to $24.00 by Analysts at CIBC (americanbankingnews.com)
- Cara Therapeutics (CARA) Rating Reiterated by BMO Capital Markets (americanbankingnews.com)
- Cara Therapeutics (CARA) Price Target Raised to $26.00 (americanbankingnews.com)
- Hot Stock to Track – Cara Therapeutics, Inc. (NASDAQ: CARA) (wallstreetnews24.com)
Shares of NASDAQ CARA traded down $0.22 during mid-day trading on Thursday, reaching $12.05. The company had a trading volume of 505,394 shares, compared to its average volume of 1,043,468. The company has a market capitalization of $384.44, a price-to-earnings ratio of -6.48 and a beta of 2.96. Cara Therapeutics has a 52-week low of $11.11 and a 52-week high of $28.50.
CARA has been the topic of a number of recent analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $17.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Seaport Global Securities initiated coverage on shares of Cara Therapeutics in a research report on Friday, January 19th. They issued a “buy” rating and a $27.00 price objective on the stock. Janney Montgomery Scott raised shares of Cara Therapeutics from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $27.00 to $21.00 in a research report on Monday, February 12th. Finally, ValuEngine raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.59.
In related news, CEO Derek T. Chalmers sold 12,500 shares of the stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $15.00, for a total transaction of $187,500.00. Following the completion of the sale, the chief executive officer now owns 1,073,792 shares in the company, valued at approximately $16,106,880. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $15.02, for a total transaction of $45,060.00. Following the sale, the senior vice president now owns 119,000 shares of the company’s stock, valued at approximately $1,787,380. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,900 shares of company stock valued at $538,560. 7.70% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Cara Therapeutics (NASDAQ:CARA) Earning Somewhat Positive Media Coverage, Report Shows” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://baseballnewssource.com/2018/04/05/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cara-therapeutics-cara-stock-price/2027485.html.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.